Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Expenses: 2016-2025

Historic Operating Expenses for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to $104.0 million.

  • Rhythm Pharmaceuticals' Operating Expenses rose 34.76% to $104.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.5 million, marking a year-over-year decrease of 4.63%. This contributed to the annual value of $395.6 million for FY2024, which is 51.13% up from last year.
  • Rhythm Pharmaceuticals' Operating Expenses amounted to $104.0 million in Q3 2025, which was up 10.82% from $93.8 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Operating Expenses high stood at $165.9 million for Q1 2024, and its period low was $34.4 million during Q1 2021.
  • Moreover, its 3-year median value for Operating Expenses was $77.1 million (2024), whereas its average is $85.0 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Operating Expenses spiked by 159.15% in 2024, and later tumbled by 51.94% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Operating Expenses (Quarterly) stood at $52.8 million in 2021, then fell by 3.62% to $50.9 million in 2022, then increased by 28.70% to $65.5 million in 2023, then increased by 26.85% to $83.1 million in 2024, then surged by 34.76% to $104.0 million in 2025.
  • Its Operating Expenses stands at $104.0 million for Q3 2025, versus $93.8 million for Q2 2025 and $79.7 million for Q1 2025.